Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children’s Oncology Group

PURPOSE: Gemtuzumab ozogamicin (GO), a calicheamicin-conjugated monoclonal antibody against CD33, has been used in the treatment of acute myeloid leukemia (AML). We evaluated the impact of the addition of GO to standard chemotherapy and hematopoietic stem cell transplant (HCT) in patients with FLT3/...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Tarlock, Katherine, Alonzo, Todd A, Gerbing, Robert B, Raimondi, Susana C, Hirsch, Betsy, Sung, Lillian, Pollard, Jessica A, Aplenc, Richard, Loken, Michael, Gamis, Alan S, Meshinchi, Soheil
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834220/
https://ncbi.nlm.nih.gov/pubmed/26644412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1349
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars